Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Prospective Study of Sintilimab Combination With Chemotherapy Sequential Radiotherapy for Advanced Esophageal Squamous Cell Carcinoma

NCT06138028 is registered in ClinicalTrials.gov with Qingdao Central Hospital as lead sponsor.

NCT NCT06138028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06138028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Prospective Study of Sintilimab Combination With Chemotherapy Sequential Radiotherapy for Advanced Esophageal Squamous Cell Carcinoma
Lead sponsor
Qingdao Central Hospital
Phase
Phase 2/3
Overall status
Recruiting
Start date
September 20, 2023
Completion date
October 31, 2026
Enrollment
90 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic esophageal squamous cell carcinoma